Nature's Sunshine Reports Strong Third Quarter 2025 Results
Nature's Sunshine (Nasdaq: NATR) reported Q3 2025 results with net sales up 12% to $128.3M and GAAP EPS $0.30 versus $0.23 a year earlier. Adjusted EBITDA rose 42% to $15.2M and gross margin improved 200 basis points to 73.3%. Net cash from operations for the nine months was $25.4M, cash and equivalents were $95.6M and the company ended the period with zero debt. The company repurchased 1,129,000 shares for $14.4M year-to-date. Management raised full-year 2025 guidance to $476–$480M net sales and $47–$49M adjusted EBITDA and announced CEO Ken Romanzi's appointment.
Nature's Sunshine (Nasdaq: NATR) ha riportato i risultati del terzo trimestre 2025 con vendite nette in aumento del 12% a $128,3 milioni e EPS GAAP $0,30 rispetto a $0,23 l'anno precedente. EBITDA rettificato in aumento del 42% a $15,2 milioni e il margine lordo è migliorato di 200 punti base al 73,3%. Il flusso di cassa netto dalle operazioni nei nove mesi è stato di $25,4 milioni, i contanti e equivalenti erano di $95,6 milioni e l'azienda ha chiuso il periodo con nessun debito. L'azienda ha riacquistato 1.129.000 azioni per $14,4 milioni dall'inizio dell'anno. La direzione ha alzato le previsioni per l'intero 2025 a $476–$480 milioni di vendite nette e $47–$49 milioni di EBITDA rettificato e ha annunciato la nomina del CEO Ken Romanzi.
Nature's Sunshine (Nasdaq: NATR) informó resultados del 3er trimestre de 2025 con ventas netas subieron 12% a $128,3 millones y EPS GAAP $0,30 frente a $0,23 un año antes. EBITDA ajustado subió 42% a $15,2 millones y el margen bruto se mejoró 200 puntos base a 73,3%. El flujo de efectivo neto de las operaciones en los nueve meses fue de $25,4 millones, efectivo y equivalentes fueron de $95,6 millones y la empresa terminó el periodo con deuda cero. La empresa recompró 1.129.000 acciones por $14,4 millones en lo que va del año. La dirección elevó las previsiones para todo 2025 a $476–$480 millones en ventas netas y $47–$49 millones en EBITDA ajustado y anunció el nombramiento del CEO Ken Romanzi.
네이처스 선샤인(Nasdaq: NATR)은 2025년 3분기 실적을 발표했고 매출은 12% 증가한 $128.3M이며 GAAP EPS $0.30로 1년 전 $0.23에 비해 상승했습니다. 조정 EBITDA는 42% 증가한 $15.2M이고 총 이익률은 200bp 향상되어 73.3%에 도달했습니다. 9개월 순영업현금흐름은 $25.4M, 현금성자산은 $95.6M였고 회사는 기간 말에 부채 없음으로 종료했습니다. 연초부터 지금까지 회사는 1,129,000주를 $14.4M에 재매입했습니다. 경영진은 2025년 연간 가이던스를 매출 $476–$480M, 조정 EBITDA $47–$49M으로 상향했고 Ken Romanzi CEO의 임명을 발표했습니다.
Nature's Sunshine (Nasdaq : NATR) a publié les résultats du T3 2025 avec un chiffre d'affaires net en hausse de 12% à 128,3 M$ et EPS GAAP 0,30$ contre 0,23$ l'année dernière. EBITDA ajusté en hausse de 42% à 15,2 M$ et la marge brute s'est améliorée de 200 points de base à 73,3%. Le flux de trésorerie net des activités sur neuf mois s'est élevé à 25,4 M$, les liquidités et équivalents étaient de 95,6 M$ et l'entreprise a terminé la période avec zéro dette. L'entreprise a racheté 1 129 000 actions pour 14,4 M$ à ce jour selon l'année. La direction a relevé les prévisions pour l'ensemble de 2025 à 476–480 M$ de chiffre d'affaires net et 47–49 M$ d'EBITDA ajusté et a annoncé la nomination du PDG Ken Romanzi.
Natures Sunshine (Nasdaq: NATR) meldete die Ergebnisse für das dritte Quartal 2025 mit Nettoverkäufe steigen um 12% auf $128,3 Mio. und GAAP EPS $0,30 gegenüber $0,23 im Vorjahr. Bereinigtes EBITDA stieg um 42% auf $15,2 Mio. und die Bruttomarge verbesserte sich um 200 Basispunkte auf 73,3%. Der Nettocashflow aus operativer Tätigkeit in den neun Monaten betrug $25,4 Mio., Barmittel und Äquivalente betrugen $95,6 Mio. und das Unternehmen beendete den Zeitraum mit null Verschuldung. Das Unternehmen hat bisher 1.129.000 Aktien für $14,4 Mio. zurückgekauft. Das Management hob die Jahresprognose für 2025 auf $476–$480M Nettoumsatz und $47–$49M bereinigtes EBITDA an und gab die Ernennung von CEO Ken Romanzi bekannt.
Nature's Sunshine (Nasdaq: NATR) أبلغت عن نتائج الربع الثالث من 2025 مع ارتفاع المبيعات الصافية بنسبة 12% إلى 128.3 مليون دولار وearnings per share على أساس GAAP 0.30 دولار مقابل 0.23 دولار في العام السابق. EBITDA المعدل ارتفع بنسبة 42% إلى 15.2 مليون دولار وهامش الهامش الإجمالي تحسن بمقدار 200 نقطة أساس ليصل إلى 73.3%. صافي النقد من العمليات للثمانية شهور كان 25.4 مليون دولار، النقدية والمعادلات/المكافئات كانت 95.6 مليون دولار وأكملت الشركة الفترة بدون ديون بلا ديون. الشركة أعادت شراء 1,129,000 سهمًا مقابل 14.4 مليون دولار حتى تاريخه. الإدارة رفعت التوقعات للعام 2025 بأكمله إلى 476–480 مليون دولار من المبيعات الصافية و47–49 مليون دولار EBITDA المعدل وأعلنت تعيين الرئيس التنفيذي Ken Romanzi.
- Net sales +12% YoY to $128.3M
- Adjusted EBITDA +42% YoY to $15.2M
- Gross margin up 200 bps to 73.3%
- Raised full-year 2025 guidance to $476–$480M net sales
- Cash $95.6M and zero debt
- Repurchased 1,129,000 shares for $14.4M
- SG&A expense increased ~11.5% to $45.7M
- Other income, net declined from $2.6M to $0.7M
- Net income attributable to NSP China fell from $1.5M to $1.0M
Insights
Strong Q3: double‑digit revenue growth, margin expansion, raised guidance and buybacks signal materially improved operating performance.
Net sales rose 12% to
These facts indicate the business scaled revenue and converted more into operating profit during the quarter, aided by cost savings and favorable mix. Key dependencies include sustainability of the
Net Sales up
Adjusted EBITDA up
Raised Full-Year Outlook
LEHI, Utah, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products, Inc. (Nasdaq: NATR) ("Nature’s Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Financial Summary vs. Same Year-Ago Quarter
- Net sales were up
12% to$128.3 million compared to$114.6 million (up10% in constant currency). - Gross profit margin increased 200 basis points to
73.3% compared to71.3% . - GAAP net income attributable to common shareholders was
$5.3 million , or$0.30 per diluted common share, compared to$4.3 million , or$0.23 per diluted common share. - Adjusted EBITDA was up
42% to$15.2 million compared to$10.7 million .
Management Commentary
“The momentum in our business continued to accelerate in the third quarter, with record net sales of
“Finally, we also saw strong benefit from our cost saving initiatives as gross margin increased 200 basis points to
Commenting on his recent appointment, Romanzi said: “I’m thrilled to join Nature’s Sunshine at such an exciting time. With strong fundamentals, a focused strategy, and an energized team, we’re well-positioned to build on our momentum and deliver continued growth and value creation as we close out the year.”
Third Quarter 2025 Financial Results
| Net Sales by Operating Segment(Amounts in Thousands) | ||||||||||||||||
| Three Months Ended September 30, | 2025 | 2024 | Percent Change | Impact of Currency Exchange | Percent Change Excluding Impact of Currency | |||||||||||
| Asia | $ | 64,725 | $ | 55,293 | 17.1 | % | $ | 1,213 | 14.9 | % | ||||||
| Europe | 22,107 | 19,615 | 12.7 | 528 | 10.0 | |||||||||||
| North America | 36,224 | 33,631 | 7.7 | (22 | ) | 7.8 | ||||||||||
| Latin America and Other | 5,283 | 6,076 | (13.1 | ) | 14 | (13.3 | ) | |||||||||
| $ | 128,339 | $ | 114,615 | 12.0 | % | $ | 1,733 | 10.5 | % | |||||||
Net sales in the third quarter increased
Gross profit margin in the third quarter increased to
Volume incentives as a percentage of net sales were
Selling, general and administrative expenses ("SG&A") in the third quarter were
Operating income in the third quarter increased to
Other income, net, in the third quarter of 2025 was
GAAP net income attributable to common shareholders increased to
Adjusted EBITDA in the third quarter increased
Balance Sheet and Cash Flow
Net cash provided by operating activities was
Outlook
Nature's Sunshine is raising its full year outlook, expecting 2025 net sales to range between
Conference Call
The Company will hold a conference call today at 5:00 p.m. Eastern time to discuss its third quarter of 2025 results.
Date: Thursday, November 6, 2025
Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)
Toll-free dial-in number: 1-800-717-1738
International dial-in number: 1-646-307-1865
Conference ID: 34830
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 1-949-574-3860.
The conference call will be broadcast live and available for replay here and via the Events section of the Nature’s Sunshine website here.
A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through Thursday, November 20, 2025.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 1134830
About Nature’s Sunshine Products
Nature’s Sunshine Products (Nasdaq: NATR), a leading natural health and wellness company, markets and distributes nutritional and personal care products in more than 40 countries. Nature’s Sunshine manufactures most of its products through its own state-of-the-art facilities to ensure its products continue to set the standard for the highest quality, safety, and efficacy on the market today. Additional information about the company can be obtained at its website, www.naturessunshine.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements regarding the Company’s future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including expected improvements in gross profit and gross margin. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including the following:
- extensive government regulations to which the Company’s products, business practices and manufacturing activities are subject, including, but not limited to, trade restrictions and export controls;
- registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets;
- legal challenges to the Company’s direct selling program or to the classification of its independent consultants;
- laws and regulations regarding direct selling may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets;
- liabilities and obligations arising from improper activity by the Company’s independent consultants;
- product liability claims;
- impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
- the Company’s ability to attract and retain independent consultants;
- the loss of one or more key independent consultants who have a significant sales network;
- the effect of fluctuating foreign exchange rates;
- failure of the Company’s independent consultants to comply with advertising laws;
- changes to the Company’s independent consultants' compensation plans;
- geopolitical issues and conflicts, including changes to U.S. trade policy resulting in new or additional tariffs;
- negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company’s customers to purchase products;
- risks associated with the manufacturing of the Company’s products;
- supply chain disruptions, manufacturing interruptions or delays, or the failure to accurately forecast customer demand;
- failure to timely and effectively obtain shipments of products from our suppliers and contract manufacturers and deliver products to our independent consultants and customers;
- world-wide slowdowns and delays related to supply chain, ingredient shortages and logistical challenges;
- uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto;
- changes in tax laws, treaties or regulations, or their interpretation;
- failure to maintain an effective system of internal controls over financial reporting;
- cybersecurity threats and exposure to data loss;
- the storage, processing, and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations;
- reliance on information technology infrastructure; and
- the sufficiency of trademarks and other intellectual property rights.
These and other risks and uncertainties that could cause actual results to differ from predicted results are more fully detailed under the caption “Risk Factors” in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports filed on Form 10-Q.
All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this press release. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this press release.
Non-GAAP Financial Measures
We have included information which has not been prepared in accordance with generally accepted accounting principles (GAAP), such as information concerning non-GAAP net income, adjusted EBITDA and net sales excluding the impact of foreign currency exchange fluctuations.
We believe that these non-GAAP measures provide investors with greater transparency to evaluate operational activities and financial results and facilitate consistent comparisons to the historical operating performance of prior periods. We utilize these non-GAAP measures of non-GAAP net income and adjusted EBITDA in the evaluation of our operations and believe that these measures are useful indicators of our operating performance and ability to fund our business. These non-GAAP financial measures should not be considered as an alternative to, or more meaningful than, U.S. GAAP net income (loss) as an indicator of our operating performance.
Other companies may use the same or similarly named measures, but exclude different items, which may not provide investors with a comparable view of Nature’s Sunshine Products’ performance in relation to other companies. We have included a reconciliation of net income, the most comparable GAAP measure, to adjusted EBITDA. We have also included a reconciliation of GAAP net income to non-GAAP net income and non-GAAP adjusted EPS, in the attached financial tables.
Net sales in local currency removes, from net sales in U.S. dollars, the impact of changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries. This is accomplished by translating the current period's net sales into U.S. dollars using the same foreign currency exchange rates that were used to translate the net sales for the previous comparable period.
We believe presenting the impact of foreign currency fluctuations is useful to investors because it allows a more meaningful comparison of net sales of our foreign operations from period to period. Net sales excluding the impact of foreign currency fluctuations should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
With respect to our adjusted EBITDA outlook for the full year 2025, a quantitative reconciliation to the corresponding GAAP information cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted, including but not limited to warrant liabilities and stock based compensation. For the same reasons, we are unable to assess the probable significance of the unavailable information, which could have a material impact on our future GAAP financial results.
Investor Relations:
Gateway Group, Inc.
Cody Slach
1-949-574-3860
NATR@gateway-grp.com
| NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Amounts in thousands, except per share information) (Unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net sales | $ | 128,339 | $ | 114,615 | $ | 356,337 | $ | 336,159 | |||||||
| Cost of sales | 34,290 | 32,856 | 98,392 | 96,535 | |||||||||||
| Gross profit | 94,049 | 81,759 | 257,945 | 239,624 | |||||||||||
| Operating expenses: | |||||||||||||||
| Volume incentives | 39,348 | 35,521 | 108,552 | 103,784 | |||||||||||
| Selling, general and administrative | 45,726 | 40,954 | 129,972 | 120,295 | |||||||||||
| Operating income | 8,975 | 5,284 | 19,421 | 15,545 | |||||||||||
| Other income: | |||||||||||||||
| Interest and other income (loss), net | 51 | (13 | ) | 524 | 462 | ||||||||||
| Interest expense | (26 | ) | (26 | ) | (71 | ) | (141 | ) | |||||||
| Foreign exchange gains, net | 672 | 2,654 | 4,451 | 1,111 | |||||||||||
| 697 | 2,615 | 4,904 | 1,432 | ||||||||||||
| Income before provision for income taxes | 9,672 | 7,899 | 24,325 | 16,977 | |||||||||||
| Provision for income taxes | 4,137 | 3,253 | 8,387 | 8,353 | |||||||||||
| Net income | 5,535 | 4,646 | 15,938 | 8,624 | |||||||||||
| Net income attributable to noncontrolling interests | 201 | 299 | 524 | 607 | |||||||||||
| Net income attributable to common shareholders | $ | 5,334 | $ | 4,347 | $ | 15,414 | $ | 8,017 | |||||||
| Basic and diluted net income per common share: | |||||||||||||||
| Basic earnings per share attributable to common shareholders | $ | 0.30 | $ | 0.23 | $ | 0.85 | $ | 0.43 | |||||||
| Diluted earnings per share attributable to common shareholders | $ | 0.30 | $ | 0.23 | $ | 0.83 | $ | 0.42 | |||||||
| Weighted average basic common shares outstanding | 17,638 | 18,512 | 18,174 | 18,661 | |||||||||||
| Weighted average diluted common shares outstanding | 18,034 | 18,890 | 18,563 | 19,115 | |||||||||||
| NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands) (Unaudited) | |||||||
| September 30, 2025 | December 31, 2024 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 95,554 | $ | 84,700 | |||
| Accounts receivable, net of allowance for doubtful accounts of | 15,114 | 9,477 | |||||
| Inventories | 67,335 | 59,443 | |||||
| Prepaid expenses and other | 8,081 | 6,959 | |||||
| Total current assets | 186,084 | 160,579 | |||||
| Property, plant and equipment, net | 33,972 | 39,585 | |||||
| Operating lease right-of-use assets | 12,963 | 12,799 | |||||
| Restricted investment securities - trading | 1,107 | 915 | |||||
| Deferred income tax assets | 20,360 | 17,644 | |||||
| Other assets | 10,319 | 9,333 | |||||
| Total assets | $ | 264,805 | $ | 240,855 | |||
| Liabilities and Shareholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 7,119 | $ | 8,912 | |||
| Accrued volume incentives and service fees | 25,387 | 20,563 | |||||
| Accrued liabilities | 31,407 | 25,399 | |||||
| Deferred revenue | 7,536 | 2,774 | |||||
| Income taxes payable | 7,599 | 4,117 | |||||
| Current portion of operating lease liabilities | 4,601 | 3,927 | |||||
| Total current liabilities | 83,649 | 65,692 | |||||
| Liability related to unrecognized tax benefits | 444 | 628 | |||||
| Long-term portion of operating lease liabilities | 9,687 | 10,277 | |||||
| Deferred compensation payable | 1,107 | 915 | |||||
| Deferred income tax liabilities | 1,075 | 1,007 | |||||
| Other liabilities | 2,139 | 1,345 | |||||
| Total liabilities | 98,101 | 79,864 | |||||
| Commitments and contingencies | |||||||
| Shareholders’ equity: | |||||||
| Common stock, no par value, 50,000 shares authorized, 17,560 and 18,483 shares issued and outstanding, respectively | 103,553 | 114,577 | |||||
| Retained earnings | 72,821 | 57,407 | |||||
| Noncontrolling interest | 6,202 | 5,678 | |||||
| Accumulated other comprehensive loss | (15,872 | ) | (16,671 | ) | |||
| Total shareholders’ equity | 166,704 | 160,991 | |||||
| Total liabilities and shareholders’ equity | $ | 264,805 | $ | 240,855 | |||
| NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands) (Unaudited) | ||||||||
| Nine Months Ended September 30, | 2025 | 2024 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net income | $ | 15,938 | $ | 8,624 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 10,538 | 10,195 | ||||||
| Non-cash lease expense | 3,792 | 4,386 | ||||||
| Share-based compensation expense | 4,223 | 3,580 | ||||||
| Loss on sale of property, plant and equipment | — | 1,330 | ||||||
| Deferred income taxes | (2,104 | ) | 26 | |||||
| Purchase of trading investment securities | (94 | ) | (126 | ) | ||||
| Proceeds from sale of trading investment securities | 14 | 95 | ||||||
| Realized and unrealized gains on investments | (112 | ) | (113 | ) | ||||
| Foreign exchange gains | (4,451 | ) | (1,111 | ) | ||||
| Changes in assets and liabilities: | ||||||||
| Accounts receivable | (5,254 | ) | (2,563 | ) | ||||
| Inventories | (6,428 | ) | 4,392 | |||||
| Prepaid expenses and other current assets | (1,323 | ) | (3,588 | ) | ||||
| Other assets | (465 | ) | (444 | ) | ||||
| Accounts payable | (2,401 | ) | 838 | |||||
| Accrued volume incentives and service fees | 4,165 | (876 | ) | |||||
| Accrued liabilities | 5,412 | (7,759 | ) | |||||
| Deferred revenue | 4,615 | (46 | ) | |||||
| Lease liabilities | (3,883 | ) | (4,492 | ) | ||||
| Income taxes payable | 2,814 | 180 | ||||||
| Liability related to unrecognized tax benefits | 235 | 442 | ||||||
| Deferred compensation payable | 192 | 144 | ||||||
| Net cash provided by operating activities | 25,423 | 13,114 | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of property, plant and equipment | (4,143 | ) | (8,776 | ) | ||||
| Net cash used in investing activities | (4,143 | ) | (8,776 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from revolving credit facility | 1,823 | 40,172 | ||||||
| Principal payments of revolving credit facility | (1,823 | ) | (40,172 | ) | ||||
| Payments related to tax withholding for net-share settled equity awards | (872 | ) | (893 | ) | ||||
| Repurchase of common stock | (14,376 | ) | (8,436 | ) | ||||
| Net cash used in financing activities | (15,248 | ) | (9,329 | ) | ||||
| Effect of exchange rates on cash and cash equivalents | 4,822 | 1,322 | ||||||
| Net increase (decrease) in cash and cash equivalents | 10,854 | (3,669 | ) | |||||
| Cash and cash equivalents at the beginning of the period | 84,700 | 82,373 | ||||||
| Cash and cash equivalents at the end of the period | $ | 95,554 | $ | 78,704 | ||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for income taxes, net of refunds | $ | 7,699 | $ | 9,782 | ||||
| Cash paid for interest | 71 | 141 | ||||||
| NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA (Amounts in thousands) (Unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net income | $ | 5,535 | $ | 4,646 | $ | 15,938 | $ | 8,624 | |||||||
| Adjustments: | |||||||||||||||
| Depreciation and amortization | 3,539 | 3,536 | 10,538 | 10,195 | |||||||||||
| Share-based compensation expense | 1,285 | 950 | 4,223 | 3,580 | |||||||||||
| Other income, net* | (697 | ) | (2,615 | ) | (4,904 | ) | (1,432 | ) | |||||||
| Provision for income taxes | 4,137 | 3,253 | 8,387 | 8,353 | |||||||||||
| Other adjustments (1) | 1,386 | 957 | 3,239 | 957 | |||||||||||
| Adjusted EBITDA | $ | 15,185 | $ | 10,727 | $ | 37,421 | $ | 30,277 | |||||||
| (1) Other adjustments | |||||||||||||||
| Other non-recurring expenses | $ | 1,386 | $ | 957 | $ | 3,239 | $ | 957 | |||||||
| Total adjustments | $ | 1,386 | $ | 957 | $ | 3,239 | $ | 957 | |||||||
* Other (income) loss, net is primarily comprised of foreign exchange (gains) losses, interest income, and interest expense.
| NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME and NON-GAAP ADJUSTED EPS (Amounts in thousands) (Unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net income | $ | 5,535 | $ | 4,646 | $ | 15,938 | $ | 8,624 | |||||||
| Adjustments: | |||||||||||||||
| Other non-recurring expenses | 1,386 | 957 | 3,239 | 957 | |||||||||||
| Tax impact of adjustments | (347 | ) | (155 | ) | (810 | ) | (155 | ) | |||||||
| Total adjustments | 1,039 | 802 | 2,429 | 802 | |||||||||||
| Non-GAAP net income | $ | 6,574 | $ | 5,448 | $ | 18,367 | $ | 9,426 | |||||||
| Reported income attributable to common shareholders | $ | 5,334 | $ | 4,347 | $ | 15,414 | $ | 8,017 | |||||||
| Total adjustments | 1,039 | 802 | 2,429 | 802 | |||||||||||
| Non-GAAP net income attributable to common shareholders | $ | 6,373 | $ | 5,149 | $ | 17,843 | $ | 8,819 | |||||||
| Basic income per share, as reported | $ | 0.30 | $ | 0.23 | $ | 0.85 | $ | 0.43 | |||||||
| Total adjustments, net of tax | 0.06 | 0.04 | 0.13 | 0.04 | |||||||||||
| Basic income per share, as adjusted | $ | 0.36 | $ | 0.27 | $ | 0.98 | $ | 0.47 | |||||||
| Diluted income per share, as reported | $ | 0.30 | $ | 0.23 | $ | 0.83 | $ | 0.42 | |||||||
| Total adjustments, net of tax | 0.06 | 0.04 | 0.13 | 0.04 | |||||||||||
| Diluted income per share, as adjusted | $ | 0.36 | $ | 0.27 | $ | 0.96 | $ | 0.46 | |||||||